Toward Project Optimus for Oncology Precision Medicine: Multi-Dimensional Dose Optimization Enabled by Quantitative Clinical Pharmacology

被引：25
作者：
Venkatakrishnan, Karthik [1 ]
van der Graaf, Piet H. [2 ]
机构：
[1] EMD Serono Res & Dev Inst Inc, Billerica, MA 01821 USA
[2] Certara UK Ltd, Certara QSP, Sheffield, S Yorkshire, England
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2022年 / 112卷 / 05期
关键词：
D O I：
10.1002/cpt.2742
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：927 / 932
页数：6
相关论文
共 35 条
[1]  
[Anonymous], Project Optimus: reforming the dose optimization and dose selection paradigm in oncology
[2]  
[Anonymous], DRAFT GUID US CIRC T
[3]  
[Anonymous], DRUG APPR PACK SCEMB
[4]  
[Anonymous], About us
[5]   Mechanistic Quantitative Pharmacology Strategies for the Early Clinical Development of Bispecific Antibodies in Oncology [J].
Betts, Alison ;
van der Graaf, Piet H. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (03) :528-541
[6]   Quantitative Systems Pharmacology Approaches for Immuno-Oncology: Adding Virtual Patients to the Development Paradigm [J].
Chelliah, Vijayalakshmi ;
Lazarou, Georgia ;
Bhatnagar, Sumit ;
Gibbs, John P. ;
Nijsen, Marjoleen ;
Ray, Avijit ;
Stoll, Brian ;
Thompson, R. Adam ;
Gulati, Abhishek ;
Soukharev, Serguei ;
Yamada, Akihiro ;
Weddell, Jared ;
Sayama, Hiroyuki ;
Oishi, Masayo ;
Wittemer-Rump, Sabine ;
Patel, Chirag ;
Niederalt, Christoph ;
Burghaus, Rolf ;
Scheerans, Christian ;
Lippert, Joerg ;
Kabilan, Senthil ;
Kareva, Irina ;
Belousova, Natalya ;
Rolfe, Alex ;
Zutshi, Anup ;
Chenel, Marylore ;
Venezia, Filippo ;
Fouliard, Sylvain ;
Oberwittler, Heike ;
Scholer-Dahirel, Alix ;
Lelievre, Helene ;
Bottino, Dean ;
Collins, Sabrina C. ;
Nguyen, Hoa Q. ;
Wang, Haiqing ;
Yoneyama, Tomoki ;
Zhu, Andy Z. X. ;
van der Graaf, Piet H. ;
Kierzek, Andrzej M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 (03) :605-618
[7]   Response to "Lorlatinib Exposed: A Far from Optimal Dose" [J].
Chen, Joseph ;
Ruiz-Garcia, Ana ;
James, Leonard P. ;
Peltz, Gerson ;
Thurm, Holger ;
Clancy, Jill ;
Hibma, Jennifer .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (06) :1197-1198
[8]   Lorlatinib Exposure-Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit-Risk Assessment in Non-Small Cell Lung Cancer [J].
Chen, Joseph ;
Ruiz-Garcia, Ana ;
James, Leonard P. ;
Peltz, Gerson ;
Thurm, Holger ;
Clancy, Jill ;
Hibma, Jennifer .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (05) :1273-1281
[9]   Exposure-Efficacy Analysis of Asciminib in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase [J].
Combes, Francois Pierre ;
Li, Ying Fei ;
Hoch, Matthias ;
Lorenzo, Sebastien ;
Ho, Yu-Yun ;
Sy, Sherwin K. B. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (05) :1040-1050
[10]   Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies [J].
De Buck, Stefan S. ;
Jakab, Annamaria ;
Boehm, Markus ;
Bootle, Douglas ;
Juric, Dejan ;
Quadt, Cornelia ;
Goggin, Timothy K. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (03) :543-555
1234